Ignite Creation Date:
2024-05-11 @ 8:31 AM
Last Modification Date:
2024-10-26 @ 3:29 PM
Study NCT ID:
NCT06404671
Status:
RECRUITING
Last Update Posted:
2024-05-08
First Post:
2024-05-01
Brief Title:
Timing of Surgery After Neoadjuvant Chemotherapy for Advanced Ovarian Cancer
Sponsor:
Alexandria University
Organization:
Alexandria University
Study Overview
Official Title:
Timing of Surgery After Neoadjuvant Chemotherapy for Advanced Ovarian Cancer A Randomized Clinical Trial for Early Versus Delayed Interval Cytoreductive Surgery
Status:
RECRUITING
Status Verified Date:
2024-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Ovarian cancer is among the top five primary causes of cancer-related mortality in women Most ovarian malignant tumours originate from epithelial cells The majority of patients typically have advanced-stage tumours at diagnosis When complete surgery with no macroscopic visible disease is not feasible due to both the spread of the disease and the patients general condition neoadjuvant chemotherapy NACT of 3 cycles followed by interval cytoreductive surgery ICS or final cytoreductive surgery FCS after 6 cycles of NACT followed or not by adjuvant chemotherapy can be offered with similar overall survival In our centre due to logistics disease or patient factors many patients may receive more than 3 cycles of NACT before ICS Therefore this randomized controlled trial aims to evaluate the survival benefit of different timings of ICS after 3 or 6 cycles of NACT in patients not eligible for upfront cytoreductive surgery UCS
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None